Core Viewpoint - Company is facing challenges in the in vitro diagnostic (IVD) industry due to intensified competition and demand pressure, leading to a decline in revenue and profit in the first half of 2025 [2][10]. Group 1: Financial Performance - In the first half of 2025, the company achieved revenue of 1.246 billion yuan, a year-on-year decrease of 20.92%, and a net profit attributable to shareholders of 189 million yuan, down 46.82% [10]. - The second quarter of 2025 saw a single-quarter revenue of 445 million yuan, a decline of 37.64%, and a net profit of only 6.35 thousand yuan, down 99.95% [10]. - The company's accounts receivable at the end of the first half of 2025 stood at 1.19 billion yuan, slightly up from 1.12 billion yuan at the beginning of the year but down 12.5% from 1.36 billion yuan at the end of the first quarter [4]. Group 2: Business Strategy and Development - The company is focusing on IPD transformation to strengthen core competitiveness and is committed to innovation in the immunology field while expanding its technical capabilities [2]. - The company is implementing a strategy of "combination, internationalization, and digitalization" to become a globally trusted IVD enterprise [4]. - The international department has expanded its operations to over 150 countries and regions, with a focus on local operations and increasing the proportion of local employees [4][5]. Group 3: Product Development and Market Expansion - In the infectious disease testing sector, the company is enhancing the coverage of flu testing products and pushing for the introduction of new respiratory disease detection products [3]. - The company has launched the Ucare-6000 fully automated blood gas and biochemical analyzer in the domestic market, providing cost-effective solutions for hospitals [3]. - The company is also focusing on the North American toxicology testing market, achieving significant sales on platforms like Amazon [3][7]. Group 4: Future Outlook - The company anticipates a stable development in its fluorescence business and aims to enhance its product offerings in grassroots medical institutions [8]. - The international department's performance in the first half of 2025 has laid a solid foundation for achieving annual performance targets [9]. - The company is committed to addressing external pressures through strategic adjustments and is optimistic about opportunities in international markets, particularly in the "Belt and Road" regions and the U.S. market [9].

2025 年 8 月 20 日│中国内地 生物医药 公司 1H25 实现收入 12.46 亿元（yoy-20.9%）、归母净利 1.89 亿元 （yoy-46.8%），主因国内行业政策变化短期压制院端需求释放且 1H25 国 内呼吸道传染病流行强度弱于 24 年同期，叠加公司强化销售及研发投入力 度。考虑公司产品布局持续拓展且国内外销售网络积极完善，看好公司业务 长期成长性。维持"买入"。 持续强化产品推广及新品研发力度 证券研究报告 万孚生物 (300482 CH) 美国子公司领衔 1H25 整体收入增长 公司 1H25 毛利率为 62.9%（yoy-1.5pct），我们推测主因国内行业政策变 化短期影响院端检测产品价格。公司 1H25 销售/管理/研发费用率分别为 25.6%/7.3%/14.0%（yoy+5.4/+0.5/+1.5pct），公司持续完善海内外商业化 推广渠道及新品研发布局，夯实长期发展基础。 美国子公司 1H25 收入实现较快增长 1）美国子公司业务：我们推测 1H25 收入同增近 20%；考虑毒检业务基本 盘稳固，叠加呼吸道检测等新品持续发力，看好美国子公司 25 年收入实现 稳健增长 ...